SCHEDULE: State Street Discloses 5.4% Stake in Apellis Pharmaceuticals

State Street Corporation has reported beneficial ownership of 5.4% of Apellis Pharmaceuticals Inc. common stock as of March 31, 2026.

Summary

• State Street Corporation, through its subsidiaries, has filed a Schedule 13G indicating beneficial ownership of 6,845,031 shares of Apellis Pharmaceuticals Inc. common stock.
• This represents 5.4% of the total class of securities.
• The filing date for this event is March 31, 2026.
• State Street Corporation is classified as a holding company (HC) for reporting purposes.
• The filing details shared voting power (6,603,712 shares) and shared dispositive power (6,845,031 shares).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by an institutional investor and does not contain operational or financial performance updates.

Future Outlook

This filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that this Schedule 13G filing by State Street Corporation indicates a significant institutional holding in Apellis Pharmaceuticals Inc., a biopharmaceutical company. Such filings are standard for large asset managers and signal their investment positions in publicly traded companies.

Stakeholder Impact

• Shareholders: The filing confirms State Street Corporation's substantial investment, which can be viewed as a sign of confidence in the company's prospects by a major financial institution.

Key Dates

Keywords

Schedule 13G, State Street Corporation, Apellis Pharmaceuticals Inc., Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing